Journal of the Korean Magnetic Resonance Society (한국자기공명학회논문지)

Korean Magnetic Resonance Society (한국자기공명학회)
권호 표지
DOI QR코드

DOI QR Code

Differential Diagnosis of Brain Diseases Using In Vivo Proton Magnetic Resonance Spectroscopy at 3 Tesla: A Preliminary Study

  • Shen, Yu-Lan (Department of Radiology Chonnam National University Medical School) ;
  • Kang, Heoung-Keun (Department of Radiology Chonnam National University Medical School) ;
  • Kim, Tae-Hoon (Department of Biomedical Engineering Chonnam National University Hospital) ;
  • Sundaram, Thirunavukkarasu (Department of Biomedical Engineering Chonnam National University Hospital) ;
  • Kim, Hyeong-Jung (Department of Biomedical Engineering Chonnam National University Hospital) ;
  • Jeong, Gwang-Woo (Department of Radiology Chonnam National University Medical School)
  • Published : 2009.12.20
Download PDF
⟨ Previous Next ⟩

Abstract

The purpose of this study was to evaluate the usefulness of in vivo 3T $^1H$ MRS with short TE for prescreening various brain diseases. Together with ten normal volunteers, 12 brain tumor patients(2 lymphomas, 5 malignant gliomas) and 5(benign meningiomas) and 10 brain ischemic disease patients(6 acute and 4 subacute infarctions) participated. Lymphomas showed increased intensities of Cho and Lac. Likewise, gliomas showed increased Cho and Lac, but with decreased NAA and ${\beta}\;{\gamma}$-Glx; in higher grade of gliomas, Lac, Cho, mI and Lip predominantly increased with decrease of NAA. Benign meningiomas showed increased Cho, Lac and ${\beta}\;{\gamma}$-Glx; with decreased of NAA. The alanine peak at 1.47 ppm is a neuronal marker for meningiomas. Infarctions showed increased Lac and Lip and decreased NAA, ${\alpha}$-Glx and ${\beta}\;{\gamma}$-Glx where Lac increased with decreased of ${\alpha}$-Glx in acute, and Cho, Lac and Lip increased with decrease of NAA in subacute. Elevated Lac and decreased NAA levels were more aggravated in subacute. Clinical application of the $^1H$ MRS with short TE at 3T is able to povide valuable spectral information for prescreening various brain diseases by monitoring the changes of disease-specific cerebral metabolite concentrations in vivo, and consequently, it can be applicable to assessment of differential diagnosis and malignancy as well.

Keywords

References

  1. Bihan D. L., Invest Radiol. 27, 6-11 (1992) https://doi.org/10.1097/00004424-199212002-00002
  2. Kim S. Y., Woo D. C., Bang E. J., et al. J. Kor Magn Reson. 12, 14-25 (2008)
  3. Damadian R., Science 171, 1151-53 (1971) https://doi.org/10.1126/science.171.3976.1151
  4. Tovi M, Thuomas K. A., Bergstrom K., et al. Acta Radiologica Supplementum 369, 161-63 (1986)
  5. Barker P. B., Lin D. D. M., Prog Nucl Magn Reson Spectrosc. 49, 99-128 (2006) https://doi.org/10.1016/j.pnmrs.2006.06.002
  6. Chiang I. C., Kuo Y. T., Lu C. Y., et al. Neuroradiology 46, 619-27 (2004)
  7. Cousins J. P., Am J Roentgenol. 164, 1337-47 (1995) https://doi.org/10.2214/ajr.164.6.7754871
  8. Braunova Z., Kasparova S., Mlynarik V., et al. Cell Mol Neurobiol. 20, 703-15 (2000) https://doi.org/10.1023/A:1007002925592
  9. Laptook A. R., Corbett R. J., Sterett R., Garcia D., Tollefsbol G., Pediatr Res.38, 919-25 (1995) https://doi.org/10.1203/00006450-199512000-00015
  10. Weiner M. W., Invest Radiol. 23, 253-61 (1988) https://doi.org/10.1097/00004424-198804000-00003
  11. Howe F. A., Maxwell R. J., Saunders D. E., Brown M. M., Griffiths J. R., Magn Reson Q. 9, 31-59 (1993)
  12. Sappey-Marinier D., Calabrese G., Hetherington H. P., et al. Magn Reson Med. 26, 313-27 (1992) https://doi.org/10.1002/mrm.1910260211
  13. Burtscher I. M., Skagerberg G., Geijer B., Englund E., Stahlberg F., Holtas S., Am J Neuroradiol 21, 84-93 (2000)
  14. Poptani H., Gupta R. K., Roy R., Pandey R., Jain V. K., Chhabra D. K., Am J Neuroradiol 16, 1593-603 (1995)
  15. Weybright P., Sundgren P. C., Maly P., et al. Am J Roentgenol 185, 1471-76 (2005) https://doi.org/10.2214/AJR.04.0933
  16. Choi C. B., Hong S. T., Choe B. Y., et al. J Kor Magn Reson. 10, 105-14 (2006)
  17. Jeong G.. W., Kang H. K., Concepts Magn Resonance 18A, 146-156 (2003) https://doi.org/10.1002/cmr.a.10071
  18. Overloop K., Van Hecke P., Vanstapel F., et al. NMR Biomed. 9, 315-21 (1996) https://doi.org/10.1002/(SICI)1099-1492(199610)9:7<315::AID-NBM429>3.0.CO;2-Z
  19. Radda G. K., Rajagopalan B., Taylor D. J., Magn Reson Q. 5, 122-51 (1989)
  20. Christiansen P., Henriksen O., Stubgaard M., Gideon P., Larsson H. B., Magn Reson Imaging 11, 107-18 (1993) https://doi.org/10.1016/0730-725X(93)90418-D
  21. Bottomley P. A., Radiology 170, 1-15 (1989) https://doi.org/10.1148/radiology.170.1.2642336
  22. Castillo M., Kwock L., Mukherji S. K., AJNR Am J Neuroradiol 17, 1-15 (1996)
  23. Hashimoto K., Engberg G., Shimizu E., Nordin C., Lindstrom L. H., Iyo M., BMC Psychiatry 5, 6-10 (2005) https://doi.org/10.1186/1471-244X-5-6
  24. Gillard J. H., Barker P. B., van Zijl P. C., Bryan R. N., Oppenheimer S. M., Am J Neuroradiol 17, 873-86 (1996)
  25. Barker P. B., Seminars in Cerebrovascular Diseases and Stroke 1, 331-42 (2001) https://doi.org/10.1053/scds.2001.29101
  26. Bartha R., Drost D. J., Menon R. S., Williamson P. C., Magn Reson Med. 44, 185-92 (2000) https://doi.org/10.1002/1522-2594(200008)44:2<185::AID-MRM4>3.0.CO;2-V
  27. Barker P. B., Hearshen D. O., Boska M. D., Magn Reson Med. 45, 765-69 (2001) https://doi.org/10.1002/mrm.1104
  28. Weybright P., Ma1y P., Gomez-Hassan D., Blaesing C., Sundgren P. C., Neuroradiology 46, 541-49 (2004)
  29. Barker P. B., Ann Neurol 49, 423-24 (2001) https://doi.org/10.1002/ana.90
  30. Danielsen E. R., Ross B., Magnetic Resonance Spectroscopy Diagnosis of Neurological Diseases. New York, Basel MARCEL DEKKER, INC. 6. (1999)
  31. Clark J. B., Developmental Neuroscience 20, 271-76 (1998) https://doi.org/10.1159/000017321
  32. Ott D., Hennig J., Ernst T., Radiology 186, 745-72 (1993) https://doi.org/10.1148/radiology.186.3.8430183
  33. Kantarci K., Knopman D. S., Dickson D. W., et al. Radiology 248, 210-20 (2008) https://doi.org/10.1148/radiol.2481071590
  34. Tien R. D., Lai P. H., Smith J. S., Lazeyras F., Am J Roentgenol 167, 201-09 (1996) https://doi.org/10.2214/ajr.167.1.8659372
  35. Negendank W. G., Sauter R., Brown T. R., Evelhoch J. L., Falini A., J Neurosurg. 84, 449-58 (1996) https://doi.org/10.3171/jns.1996.84.3.0449
  36. Meyerand M. E., Pipas J. M., Mamourian A., Tosteson T. D., Dunn J.F., Am J Neuroradiol 20, 2-3 (1999)
  37. Kuesel A. C., Sutherland G. R., Halliday W., Smith I. C., NMR Biomed. 7, 149-55 (1994) https://doi.org/10.1002/nbm.1940070308
  38. Maxwell R. J., Martinez-Perez I., Cerdan S., et al. Magn Reson Med. 39, 869-77 (1998) https://doi.org/10.1002/mrm.1910390604
  39. Michaelis T., Merboldt K. D., Bruhn H., Hanicke W., Frahm J., Radiology 187, 219-27 (1993) https://doi.org/10.1148/radiology.187.1.8451417
  40. Kwock L., Smith J. K., Castillo M., et al. Technol Cancer Res Treat. 1, 17-28 (2002) https://doi.org/10.1177/153303460200100103

Cited by

  1. Simultaneous Spectral Resolution and Sensitivity Enhancement in MR spectrum: Maximum Likelihood Deconvolution Reconstruction vol.15, pp.2, 2011, https://doi.org/10.6564/JKMRS.2011.15.2.157